{"id":8350,"date":"2020-07-20T15:36:30","date_gmt":"2020-07-20T22:36:30","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8350"},"modified":"2021-04-02T15:37:34","modified_gmt":"2021-04-02T22:37:34","slug":"articles-immunogenicity-and-safety-of-a-recombinant-adenovirus-type-5-vectored-covid-19-vaccine-in-healthy-adults-aged-18-years-or-older%e2%80%af-a-randomised-double-blind","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/20\/articles-immunogenicity-and-safety-of-a-recombinant-adenovirus-type-5-vectored-covid-19-vaccine-in-healthy-adults-aged-18-years-or-older%e2%80%af-a-randomised-double-blind\/","title":{"rendered":"Articles Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or\u00a0Older\u202f:\u00a0A\u00a0Randomised\u00a0, Double-Blind ,\u00a0Placebo-\u00a0Controlled ,\u00a0Phase 2 Trial"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2019\" data-aria-level=\"1\"><span data-contrast=\"auto\">Zhu et al. conducted a randomized, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine to determine the immunogenicity and incidence of adverse reactions.\u00a0<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">Both\u00a0 doses\u00a0\u00a0of\u00a0 the\u00a0\u00a0vaccine\u00a0 induced\u00a0\u00a0significant\u00a0 neutrali<\/span><span data-contrast=\"auto\">z<\/span><span data-contrast=\"auto\">ing\u00a0\u00a0antibody\u00a0 responses\u00a0\u00a0to\u00a0 live\u00a0 SARS-CoV-2<\/span><span data-contrast=\"auto\">. Evidence of antigen-specific T-cell responses were observed in 88-90% of vaccine recipients.<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2019\" data-aria-level=\"1\"><span data-contrast=\"auto\">Within 14 days, 72% of participants in one vaccine dose group and 74% of participants in another dose group reported at least one adverse reaction, both of which were significantly higher than the 37% of participants in the placebo group. Common reactions included fatigue, fever, headache, and pain at the injection site. However, no serious adverse events were documented within 28 days after\u00a0injection.\u00a0<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Zhu et al. (July 20, 2020). Articles Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or\u00a0Older\u202f:\u00a0A\u00a0Randomised\u00a0, Double-Blind ,\u00a0Placebo-\u00a0Controlled ,\u00a0Phase 2 Trial. The Lancet.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(20)31605-6\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1016\/S0140-6736(20)31605-6<\/span><\/a><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zhu et al. conducted a randomized, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine to determine the immunogenicity and incidence of adverse reactions.\u00a0\u00a0 Both\u00a0 doses\u00a0\u00a0of\u00a0 the\u00a0\u00a0vaccine\u00a0 induced\u00a0\u00a0significant\u00a0 neutralizing\u00a0\u00a0antibody\u00a0 responses\u00a0\u00a0to\u00a0 live\u00a0 SARS-CoV-2. Evidence of antigen-specific T-cell responses were observed in 88-90% of vaccine recipients.\u00a0 Within 14 days, 72% of participants in one vaccine dose&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/20\/articles-immunogenicity-and-safety-of-a-recombinant-adenovirus-type-5-vectored-covid-19-vaccine-in-healthy-adults-aged-18-years-or-older%e2%80%af-a-randomised-double-blind\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[31],"class_list":["post-8350","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8350"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8350\/revisions"}],"predecessor-version":[{"id":8351,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8350\/revisions\/8351"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8350"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}